Study on PALB2 and Breast Cancer Risk in Iceland
Author Information
Author(s): Gunnarsson Haukur, Arason Adalgeir, Gillanders Elizabeth M, Agnarsson Bjarni A, Johannesdottir Gudrun, Johannsson Oskar Th, Barkardottir Rosa B
Primary Institution: Landspitali – University Hospital, Reykjavik, Iceland
Hypothesis
Is the PALB2 gene a significant factor in breast cancer susceptibility in Iceland?
Conclusion
The study found that PALB2 is not a significant contributor to breast cancer in high-risk families in Iceland.
Supporting Evidence
- No evidence of linkage in the PALB2 region was found in any of the high-risk breast cancer families.
- The 1592delT mutation was not detected in 638 unselected breast cancer cases or in any of the 111 family members.
- The results suggest that PALB2 is not a significant factor in breast cancer susceptibility in Iceland.
Takeaway
The researchers looked for a gene that might cause breast cancer in Iceland but found that it doesn't seem to be a problem there.
Methodology
Linkage analysis and mutation screening were performed on 111 individuals from high-risk families and 638 unselected breast cancer cases.
Limitations
The study cannot exclude the possibility that other PALB2 mutations causing low or moderate breast cancer risk exist.
Participant Demographics
111 individuals from 9 high-risk non-BRCA1/BRCA2 breast cancer families and 638 unselected breast cancer cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website